G. K. Butterfield actually said...

It is critical, therefore, that the public can depend on approved biosimilars and that we encourage the development of new treatments.

The sooner that affordable, safe, and reliable treatments are discovered, the better we are all going to be.

Let me first direct my question to you, Chairman Wheeler.

If this approach does not honor licensing terms that are negotiated between programmers and MVPDs, how would that affect the diversity of pr...